INNATE PHARMA SA (IPH.PA) Stock Price, Forecast & Analysis
Europe - EPA:IPH - FR0010331421 - Common Stock
IPH.PA Key Statistics, Chart & Performance
The current stock price of IPH.PA is 1.56 EUR. In the past month the price decreased by -12.71%. In the past year, price increased by 2.22%.
IPH.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 73.97 | 48.82B | ||
| ARGX.BR | ARGENX SE | 73.56 | 48.55B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.11B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.70B | ||
| GLPG.AS | GALAPAGOS NV | 23.37 | 1.73B | ||
| 5CV.DE | CUREVAC NV | 5.26 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 891.02M | ||
| PHIL.MI | PHILOGEN SPA | 20.22 | 673.98M | ||
| IVA.PA | INVENTIVA SA | N/A | 501.76M | ||
| FYB.DE | FORMYCON AG | N/A | 396.69M | ||
| ALCLS.PA | CELLECTIS | N/A | 370.70M |
Related stock screener links
About IPH.PA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 181
Phone: 33430303030
INNATE PHARMA SA / IPH.PA FAQ
Can you describe the business of INNATE PHARMA SA?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
What is the stock price of INNATE PHARMA SA today?
The current stock price of IPH.PA is 1.56 EUR. The price decreased by -0.38% in the last trading session.
What is the dividend status of INNATE PHARMA SA?
IPH.PA does not pay a dividend.
How is the ChartMill rating for INNATE PHARMA SA?
IPH.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in INNATE PHARMA SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IPH.PA.
What is the ownership structure of INNATE PHARMA SA (IPH.PA)?
You can find the ownership structure of INNATE PHARMA SA (IPH.PA) on the Ownership tab.
IPH.PA Technical Analysis
IPH.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IPH.PA. IPH.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
IPH.PA Financial Highlights
Over the last trailing twelve months IPH.PA reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| Debt/Equity | 11.55 |
IPH.PA Forecast & Estimates
9 analysts have analysed IPH.PA and the average price target is 5.46 EUR. This implies a price increase of 250.15% is expected in the next year compared to the current price of 1.56.
For the next year, analysts expect an EPS growth of -32.84% and a revenue growth -26.21% for IPH.PA